Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Inclusion Criteria: 1. Head and neck squamous cell carcinomas, stage I to IVb 2. First-line curative cancer therapy : surgery and/or brachytherapy and/or chemotherapy 3. HADS- T \>11 4. Aged 18 to 75 yo, written consent required 5. OMS\>2 Exclusion Criteria: 1. Palliative care 2. Previous head and neck cancer 3. Bipolar disorder or schizophrenia 4. Severe major depressive disorder (DSM-IV TR) 5. Expressed suicidal ideation 6. Severe untreated organic disorder, especially acute infectious disorder 7. ASAT/ALAT \> 3N 8. Clearance of creatinin \< 30 ml/mn 9. Hyponatremia 10. Antecedent of delirium tremens or acute alcohol withdrawal disorder 11. Antecedent of upper gastro-intestinal bleeding 12. Antecedent of toxicity or inefficacy of a previous treatment with escitalopram 13. Unauthorized treatments :- Antidepressant or antiepileptic (clonazepam authorized)- Hypnotic except zolpidem - Anxiolytic except clonazepam, clorazepate or diazepam- bupropion or varenicline 14. Pregnancy or lactation